Navigation Links
Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
Date:1/26/2009

stent and treat the diseased portion of the artery.

The XIENCE V stent is available on both over-the-wire (OTW) and rapid exchange (RX) delivery systems. Rapid exchange is the most widely used type of delivery system because it provides physicians additional flexibility to work as single operators during stent procedures.

XIENCE V was approved by the U.S. Food and Drug Administration and launched in July 2008, and was launched in Europe and other international markets in October 2006. XIENCE V is an investigational device in Japan and is currently under review by the Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.

Abbott also supplies a private-labeled XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti- proliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
2. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
5. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
8. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
11. New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014 BreedIT Corp (OTC: BRDT), through ... of highly sophisticated agro-breeding solutions for plant breeders and ... Company,s board of directors appointed chemistry and pharmaceutical industry ... member of the board. From 1975 to ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the ... Healthcare Distribution Specialist, LLC ("HDS") are pleased to announce ... Vitamin & Sports Nutrition Expo to be held at ... Florida on July 15-17, 2012.  As part of the ...
... announced today the Clinical Laboratory Responsibility Pledge, a ... ethical business practices in the medication monitoring industry. ... adheres and to which the company challenges every ... adopt. (Logo: http://photos.prnewswire.com/prnh/20120203/LA47138LOGO ) ...
Cached Medicine Technology:Sunpeaks Ventures to Participate in ECRM Conference and Expo 2Sunpeaks Ventures to Participate in ECRM Conference and Expo 3Millennium Laboratories Announces Laboratory Responsibility Pledge 2Millennium Laboratories Announces Laboratory Responsibility Pledge 3
(Date:4/18/2014)... A group of scientists from the University of ... on Aging has found interesting new information in ... Parkinson,s disease (PD). , Published in the ... assessed cognitive function in depressed and non-depressed patients ... commonly used to treat motor symptoms of Parkinson,s ...
(Date:4/18/2014)... researchers have been awarded two-year grants for their work ... month. Of the 110 initial submissions to the new ... only four projects were funded, three of which are ... M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, ... oncology, will use his $500,000 proof of principle grant ...
(Date:4/18/2014)... San Diego, Calif. (April 18, 2014) ― A new ... analyzing weekly patterns in health-related Google searches reveals ... public health strategies. , Investigators from San ... University, and the Monday Campaigns, analyzed "healthy" Google searches ... health-related, e.g., "healthy diet") originating in the U.S. from ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
Breaking Medicine News(10 mins):Health News:Treating depression in PD patients: New research 2Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2
... Expected to Achieve Strong Uptake in this ... from Decision ResourcesWALTHAM, Mass., April 30 ... research and advisory firms for pharmaceutical and ... Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s Remicade, and Abbott/Eisai,s ...
... creates federal-state-local partnership to help fight domestic violence, ... $1.1 million U.S. Justice Dept. grant is fueling ... to help combat domestic violence and sexual assault ... Appellate Prosecutor,s office has hired two full-time prosecutors ...
... steroid to multiple sclerosis treatment shows promise in study ... steroid drug in combination with a multiple sclerosis (MS) ... using the MS drug alone, suggests a new study. ... relapsing-remitting MS, some patients were randomly selected to receive ...
... of the pancreas, invagination of the pancreas into the ... fistula, according to researchers at the Jefferson Pancreas, Biliary ... the Journal of the American College of Surgeons ... the gold standard for studies. , Removing the head ...
... 2008...sales up 266%, , ... Winston-Salem, ... today that it is expanding its corporate and satellite offices ... stabilization system, VerteLoc™. , , , , ,"We are essentially ...
... principles for Getting Health IT Right under the American ... the Markle Foundation hosts a forum to discuss the ... (IT) under the American Recovery and Reinvestment Act (ARRA). ... with government and policy experts to talk about how ...
Cached Medicine News:Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 2Health News:Meaningful Investment of $19 Billion on Health Information Technology 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
The CRW system epitomizes simplicity, quality assurance, and versatility....
Used to negotiate tortuous vessels....
Hydrosteer wires are intended for use in the percutaneous introduction of catheters....
Medicine Products: